The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.

FDA Approves Mirikizumab for Crohn Disease: Daily Dose

By Sydney Jennings

January 27th 2025

Your daily dose of the clinical news you may have missed.

Landmark International Trial Seeks to Intercept and Prevent Crohn Disease Using Biomarkers

By Grace Halsey

January 22nd 2025

The INTERCEPT project aims to build a blood risk score that can identify individuals with a high risk of developing Crohn disease within 5 years of initial evaluation.

FDA Approves Lilly’s Mirikizumab-mrkz for Crohn’s Disease

By Patient Care Staff

January 16th 2025

Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.

<1 2 3

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777